In a study of rheumatoid arthritis patients, serum chemerin levels were measured before and after 6 months of treatment with tocilizumab, and it was discovered that serum chemerin levels were significantly reduced after treatment with interleukin-6 receptor inhibitor, indicating that increased chemerin levels may result in bone pathology and that decreasing chemerin levels with treatment resulted in clinical response in such patients (Makrilakis et al., 2015). The gene discussed is RARRES2; the disease is rheumatoid arthritis.